Steven Blitz, TS Lombard Chief U.S. Economist, joined Yahoo Finance to break down the latest in the markets.
Steven Blitz, TS Lombard Chief U.S. Economist, joined Yahoo Finance to break down the latest in the markets.
The euro zone will rebound from its COVID-19 slump more than expected, the European Commission said on Wednesday, but some countries won't reach pre-crisis levels before the end of 2022 -- an argument for continued suspension of EU borrowing limits. The aggregate growth of the 19 countries sharing the euro currency should be 4.3% this year and 4.4% in 2022, the European Union's executive arm said, revising upwards its forecast from February of 3.8% growth in both years. The forecast brings the Commission closer to the International Monetary Fund, which last month said it expected 4.4% growth in the euro zone this year.
TEHRAN, Iran (AP) — Iran's former firebrand president will run again for office in upcoming elections in June, raising the possibility of a bolstered hardline leadership at a time of tense negotiations with the West. Thronged by shouting supporters, Mahmoud Ahmadinejad marched to a registration center at the Interior Ministry where he filled out registration forms. He held up his hands in a “V for Victory” salute, before addressing reporters. “My presence today for registration was based on demand by millions for my participation in the election,” he said, adding that the move also came after “considering the situation of the country, and the necessity for a revolution in the management of the country.” Ahmadinejad in recent years has tried to polish his hardline image into a more centrist candidacy, criticizing the government for mismanagement. The Holocaust-denying Ahmadinejad has previously been banned from running for the presidency by Supreme Leader Ayatollah Ali Khamenei in 2017, although then, he registered anyway. A constitutional watchdog, the Guardian Council ultimately disqualified him. Khamenei says he will not oppose the nomination of any candidate, although the electoral council may still block Ahmadinejad's candidacy. In either case, the populist's return to the political scene may energize discontent among hard-liners who seek a tougher stance against the west — particularly Israel and the U.S. Iran opened registration on Tuesday, kicking off the race as uncertainty looms over Tehran’s tattered nuclear deal with world powers and tensions remain high with the West. President Hassan Rouhani can not run again due to term limits, yet with the poll just a month away no immediate favorite has emerged among the many rumored candidates. There also appears to be little interest in the vote by a public crushed by sanctions and the coronavirus pandemic. Nevertheless, many view the country’s hard-liners as ascendant — even as the U.S. under President Joe Biden tries to find a way to re-enter the atomic accord. Whoever wins the June 18 vote will take over from Rouhani, a relative moderate within the Islamic Republic whose two four-year terms began with Iran reaching the nuclear deal. His time in office now draws to a close with the accord unraveled after the U.S. unilaterally withdrew from it under President Donald Trump in 2018. Ahmadinejad pushed his nation into open confrontation with both the West over its nuclear program and its own people after his disputed 2009 re-election sparked the biggest mass protests since the country’s 1979 Islamic Revolution. Abroad, he became a caricature of Western perceptions of the Islamic Republic’s worst attributes, such as denying the Holocaust, insisting Iran had no gay or lesbian citizens and hinting Iran could build a nuclear weapon if it chose to do so. At home, however, the former Tehran mayor drew support from the countryside for his populist cash handouts and home-building programs. As his two-term presidency drew to a close and in his life after office, he also crossed the clear red line of Iran’s Shiite theocracy, directly challenging Supreme Leader Ayatollah Ali Khamenei, who has final say on all matters of state. Ahmadinejad entered office in 2005 and left in 2013, after the election of President Hassan Rouhani, who would go onto to make the nuclear deal with world powers. Yet even out of office, Ahmadinejad sought to reinvigorate his political fortunes in public and on social media. Nasser Karimi, The Associated Press
Europe's top human rights watchdog has urged Greece to end pushbacks of asylum-seekers on its borders, a practice that Athens denies carrying out. In a letter to Greek ministers dated May 3 and published on Wednesday, the Council of Europe's Human Rights Commissioner said there had been "numerous credible allegations" since at least 2017 of asylum-seekers illegally returned to Turkey or left adrift at sea but that Athens had simply dismissed them.
BGS earnings call for the period ending April 3, 2021.
Image source: The Motley Fool. helios technologies inc (NASDAQ: HLIO)Q1 2021 Earnings CallMay 11, 2021, 9:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Helios Technologies First Quarter 2021 Financial Results Conference Call.
The pound held steady above $1.41 on Wednesday after UK GDP data for March beat market expectations, keeping investors optimistic about the UK's economic recovery from the pandemic. Sterling jumped to a two-month high on Monday this week due to a combination of dollar weakness, market relief over Scottish election results, lockdown easing measures, and the Bank of England raising its forecast for economic growth. Although analysts said the data's immediate market impact was limited by the fact that it referred to a period when stricter lockdown restrictions were still in place, it helped support the market expectation for a strong recovery in the UK.
Press release – Paris, May 12, 2021 Danone intends to sell its stake in Mengniu Danone launches today the strategic sale, via an accelerated bookbuilding process, of its approximately 9.8% stake in China Mengniu Dairy Company Limited (“Mengniu”), a leading Chinese manufacturer and distributor of dairy products, which is listed on the Hong Kong Stock Exchange. This transaction follows the announcement on February 28, 2021, of the conversion of Danone’s long-term indirect stake in Mengniu into a direct holding which completed on April 16, 2021. A further announcement with regards to the success of the sale and proceeds received will be made by Danone in due course. o o O o o Note: This release is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities in Hong Kong, the United States or any other jurisdiction. This release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to above have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the Securities Act and under the securities laws of any state of other jurisdiction of the United States. About Danone (www.danone.com) Danone is a leading multi-local food and beverage company building on health-focused and fast-growing categories in 3 businesses: Essential Dairy & Plant-Based products, Waters and Specialized Nutrition. With its ‘One Planet. One Health’ frame of action, which considers the health of people and the planet as intimately interconnected, Danone aims to inspire healthier and more sustainable eating and drinking practices. To accelerate this food revolution and create superior, sustainable, profitable value for all its stakeholders, Danone has defined nine 2030 Goals, and paved the way as the first listed company to adopt the “Entreprise à Mission” status in France. With a purpose to bring health through food to as many people as possible, and corresponding social, societal and environmental objectives set out in its articles of association, Danone commits to operating in an efficient, responsible and inclusive manner, in line with the Sustainable Development Goals (SDGs) of the United Nations. By 2025, Danone aims to become one of the first multinational companies to obtain B Corp™ certification. With more than 100,000 employees, and products sold in over 120 markets, Danone generated €23.6 billion in sales in 2020. Danone’s portfolio includes leading international brands (Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danonino, evian, Nutricia, Nutrilon, Volvic, among others) as well as strong local and regional brands (including AQUA, Blédina, Bonafont, Cow & Gate, Horizon Organic, Mizone, Oikos, Prostokvashino, Silk, Vega). Listed on Euronext Paris and present on the OTCQX market via an ADR (American Depositary Receipt) program, Danone is a component stock of leading sustainability indexes including the ones managed by Vigeo Eiris and Sustainalytics, as well as the Ethibel Sustainability Index, the MSCI ESG Indexes, the FTSE4Good Index Series, Bloomberg Gender Equality Index, and the Access to Nutrition Index. o o O o o FORWARD-LOOKING STATEMENTS This press release contains certain forward-looking statements concerning Danone. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone. Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the “Risk Factor” section of Danone’s Universal Registration Document (the current version of which is available on www.danone.com). Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities. Attachment PR_Danone_120521_1
MOSCOW (AP) — Under Kremlin orders, the U.S. Embassy has stopped employing Russians, forcing the embassy to cut its consular staff by 75% and limit many of its services. The order went into effect on Wednesday, bringing the sharply deteriorating U.S.-Russia relationship to an intensely personal level. Because of the cuts, the embassy can offer only very limited services, such as considering “life-and-death” visa applications. That leaves Russian businessmen, exchange students and romantic partners adrift because they won't be able to obtain visas. Even Americans will be unable to register their newborns or renew their passports. For Anastasia Kuznetsova, a 20-year-old engaged to marry a Californian, it's a crushing blow. She had already spent about two years seeking a fiancee's visa. The notoriously laborious process for Russians to get U.S. visas had already been slowed by COVID-19. “I felt destroyed, much more depressed than I was before," said Kuznetsova, who last saw her fiance in January on a trip to Mexico. “We have no idea when it’s going to continue working and if we will be able to see each other even during these years.” Thomas H V Anthony, an American living in Russia, was already frustrated because of a delay in registering the birth of his daughter, a record of the child's claim to U.S. citizenship. “My expectation was as things get better with the situation with the pandemic, gradually the consulate would open more and more and more,” he said. “It was a big shock to suddenly get an email from them, about two weeks ago, saying effective on the 11th we will no longer be offering any consular services.” For Anthony, this means his daughter, who was born before the pandemic, will not be able to travel to visit her grandparents in the United States in the foreseeable future. The embassy has made no statements on whether it is taking measures to beef up the consular staff with new employees from the United States. Embassy spokespeople could not be reached for clarification on how the mission will handle other jobs also filled by locals, such as security. An order signed last month by President Vladimir Putin called for creating a list of “unfriendly” countries whose missions could be banned from hiring Russians or third-country nationals. The list includes the United Kingdom, Ukraine, Poland and several other European countries, but the United States is the first for which the ban is being enforced. The move followed U.S. sanctions imposed over Russian interference in the 2020 U.S. presidential election and involvement in the SolarWind hack of federal agencies. Each country expelled 10 of the other's diplomats. Foreign Minister Sergey Lavrov said the ban on local employees is in line with convention. “We rarely employ any local personnel in the country where our diplomatic mission is. And thus we have the full right to transfer this practice onto the regulations which manage the work of the U.S. Embassy and their general consulate in the Russian Federation," he said last month. Yulia Kukula, a university student who was accepted for a PhD program in sustainable energy at Arizona State University, may have found a laborious and costly way around the problem of getting her visa to attend university. After searching online for advice from others in her situation, Kukula was able to sign up for an interview for a visa at the U.S. consulate in neighboring Kazakhstan. But that's a 2,300-kilometer (1,400-mile) trip from Moscow, and the interview isn't until October. The United States once had three other consulates in Russia — in Yekaterinburg, Vladivostok and St. Petersburg — which somewhat eased the travel burden for people seeking visas. But those consulates have closed or stopped providing visas amid diplomatic spats in recent years, in what Alexis Rodzianko, head of the American Chamber of Commerce in Russia, called “a visa war.” That had already placed a burden on the companies in his chamber whose executives needed to travel. “Now it looks like it's impossible for the indefinite future,” he said. The travel restrictions of the pandemic have shown that videoconferencing can't entirely replace the in-person contact of business travel, he said. “They're especially good for people who already know each other and they're much less effective for people getting to know each other,” he said. He also sees a larger problem if the visa halt lasts for long. He worries that because the U.S. and Russian governments are adversaries, a lack of contacts between people on both sides could lead to “dehumanization,” adding, “which is very dangerous because that's what you need to fight a war.” Kuznetsova, who had hoped to celebrate her wedding in the United States this year and had even quit her university in Russia in preparation for the move, feels trapped as a small piece in a large geopolitical dispute. “I understand that there can be problems between countries, it’s normal, it’s happened throughout all of history, but it’s not normal to divide people and separate them, especially when it’s families and the lives of people,” she said. Daniel Kozin And Jim Heintz, The Associated Press
Dublin, May 12, 2021 (GLOBE NEWSWIRE) -- The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.The report contains profiles of 141 companies that have a neuroprotective product or products along with 126 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 1,100 references are included. Clinical trials of various neuroprotective agents are described and failures of trials are analyzed with suggestions for improving the selection of drugs and design of trials. The report is supplemented with 84 tables and 27 figures.Market analysis of currently used products that have a neuroprotective effect are analyzed for the year 2020. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and the takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2024 when it will constitute a major and important component of the CNS market. Forecasts are made until 2030. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.Key Topics Covered: Part One Executive Summary 1. Introduction 2. Neuroprotective Agents 3. Neuroprotection in Cerebrovascular Disease 4. Neuroprotection in Traumatic Brain Injury 5. Neuroprotection in Spinal Cord Injury 6. Neuroprotection in Neurodegenerative Disorders 7. Neuroprotection in Parkinson Disease 8. Neuroprotection in Alzheimer Disease 9. Neuroprotection in Huntington Disease 10. Neuroprotection in Amyotrophic Lateral Sclerosis 11. Neuroprotection in Miscellaneous Neurological Disorders 12. Neuroprotection of the Optic nerve and the Retina 13. Neuroprotection during Anesthesia and Surgery Part Two 14. Markets for Neuroprotective Therapies 15. Companies Developing Neuroprotective Therapies 16. References For more information about this report visit https://www.researchandmarkets.com/r/vbcpkr CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The UK economy shrank by 1.5% in the first three months of 2021, but picked up speed in March.
Refresh your wardrobe with one of these timeless, budget-friendly or statement styles
Glenn Kirschner warns the former president: "Justice is coming"
Follow below for all the latest developments from Westminster and beyond
A crash involving eight trucks left liquid egg yolk spilled across a highway near the north Italian city of Parma on May 12.One driver suffered a minor injury, the Gazzetta di Parma said.The paper also said there were long tailbacks after a tollbooth on the A1 was closed. Credit: Vigili del Fuoco via Storyful
Investors counting on the Bank of Japan to put a floor under stock prices may be disappointed as the current rout likely falls short of new thresholds set in March for its exchange-traded fund (ETF) buying, findings unveiled by the central bank show. As part of efforts to make its massive stimulus sustainable, the BOJ in March ditched a pledge to buy ETFs at a set annual pace and now promises to step in only "when necessary." Some investors have blamed recent stock falls partly on the absence of the BOJ - the biggest owner of Japanese stocks after its massive ETF buying spree last year.
Dublin, May 12, 2021 (GLOBE NEWSWIRE) -- The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021" report has been added to ResearchAndMarkets.com's offering. The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available records for over 1,100 asset purchase deals, including contract documents where available.The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of over 1,100 asset purchase deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report focuses on four primary types of asset available for purchase: Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operationsProduct assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefitRoyalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the productTechnology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation Key benefitsGlobal Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 provides the reader with the following key benefits: In-depth understanding of asset purchase deal trends since 2014Analysis of the structure of asset purchase agreements with numerous real life case studiesComprehensive access to over 1,100 actual asset purchase deals entered into by the world's biopharma companiesDetailed access to actual asset purchase deals entered into by leading biopharma companiesInsight into the terms included in a asset purchase agreement, together with real world clause examplesUnderstand the key deal terms companies have agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companies Available deals are listed by: Company A-ZHeadline valueStage of development at signingTherapeutic areaTechnology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in Asset Purchase dealmaking2.1. Introduction2.2. Types of assets purchased2.3. Trends in Asset Purchase deals since 20142.3.1. Asset Purchase dealmaking by year since 20142.3.2. Asset Purchase dealmaking by phase of development since 20142.3.3. Asset Purchase dealmaking by industry sector since 20142.3.4. Asset Purchase dealmaking by therapy area since 20142.3.5. Asset Purchase dealmaking by technology type since 20142.3.6. Asset Purchase dealmaking by most active company since 20142.4. Reasons for entering into asset purchase partnering deals2.4.1. Business assets2.4.2. Product assets2.4.3. Royalty assets2.4.4. Technology assets2.5 The emergence of royalty asset purchase deals2.5.1. Primary players in royalty asset purchase deals2.5.3. The future of royalty asset purchase deals2.6. The role of IP auction houses in asset purchase deals2.6.1. Leading IP auction companies2.7. The future of asset purchase agreementsChapter 3 - Overview of Asset Purchase deal structure3.1. Introduction3.2. Asset purchase agreement structure3.3. Example asset purchase agreements3.3.1. Case study 1: Product asset: QLT - Valeant Pharmaceuticals3.3.2. Case study 2: Business asset: Merck and Co - Bayer3.4. Anatomy of a royalty asset purchase agreement3.5. Example royalty asset purchase agreements3.5.1. Case study 3: Royalty asset: BioTime Acquisition Corporation- Geron CorporationChapter 4 - Leading Asset Purchase deals4.1. Introduction4.2. Top Asset Purchase deals by valueChapter 5 - Top 25 most active Asset Purchase dealmakers5.1. Introduction5.2. Top 25 most active Asset Purchase dealmakersChapter 6 - Asset Purchase deals including contracts directory6.1. Introduction6.2. Asset Purchase deals with contracts since 2014AppendicesAppendix 1 - Asset Purchase dealmaking by companies A-ZAppendix 2 - Asset Purchase dealmaking by industry sectorAppendix 3 - Asset Purchase dealmaking by stage of developmentAppendix 4 - Asset Purchase dealmaking by therapy areaAppendix 5 - Asset Purchase dealmaking by technology type For more information about this report visit https://www.researchandmarkets.com/r/5x1f8v CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
London City Airport’s Robert Sinclair predicted that business travel will recover from the pandemic because of the need for ‘human interaction’.
Rajeev Karwal was a part of the top management of leading electronics brands such as Onida, LG, Philips, Electrolux and Reliance Digital
Tired, wired and worried about how you’ll cope with the big office return? Help is at hand — Katie Strick presents a smart toolkit to help you find your calm (at last!)
A Cabinet minister today insisted NHS staff are getting a “modest” pay rise when questioned over popstar Dua Lipa’s Brits speech. George Eustice stressed it was a “difficult public finance environment,” after Dua Lipa used her Brit Awards acceptance speech to call for an NHS pay rise. The singer, who picked up the female solo artist award, called on Boris Johnson to give frontline staff a “fair pay rise”, adding: "It’s very good to clap for them, but we need to pay them.”